Antianginal therapy Amirhossein Azhari Electrophysiologist

1. Antianginal therapy AmirhosseinAzhari Electrophysiologist

2. Coronary Atherosclerosis • Diseases of the coronary arteries is almost always due to plaque and its complications , particularly thrombosis. • Atherosclerosis is a progressive inflammatory disorder of arterial wall that is characterized by focal lipid rich deposits of atheroma that remain clinically silent until they become large enough to impair tissue perfusion

5. Goal of therapy • The goal of therapy with antianginal agents is to restore the balance between oxygen supply and demand in the ischemic region of the myocardium.

6. High oxygen demand Low oxygen supply

7. Pharmacology of Antianginal Agents Three major classes of agents are used individually or in combination to treat angina: • Organic nitrates • Vasodilate coronary arteries • Reduce preload and aferload • Calcium channel blockers • Vasodilate coronary arteries • Reduce afterload • The non-dihydropyridines (verapamil and diltiazem) also decrease heart rate and contractility

8. Beta-adrenergic blockers • Decrease heart rate and contractility • Decrease afterload 2° to a decrease in cardiac output • Improve myocardial perfusion 2° to a decrease in heart rate • A new class of drugs, are in the final stages of approval for chronic angina • Reduce myocardial oxygen consumption by shifting metabolism from fatty acid to glucose metabolism • No hemodynamic effects

9. Nitrates • The action of these agents is to relax vascular smooth muscle. The vasodilator effects of nitrates are evident in systemic (including coronary) arteries and veins • they appear to be predominant in the venous circulation. • The venodilator effect reduces ventricular preload, which in turn reduces myocardial wall tension and O2 requirements.

10. Nitrates • All of these agents are enzymatically converted to nitric oxide (NO) in the target tissues • NO is a very short-lived endogenous mediator of smooth muscle contraction and neurotransmission • Veins and larger arteries appear to have greater enzymatic capacity than resistance vessels, resulting in greater effects in these vessels

11. NO activates a cytosolic form of guanylate cyclase in smooth muscle • Activated guanylate cyclase catalyzes the formation of cGMP which activates cGMP-dependent protein kinase • Activation of this kinase results in phosphorylation of several proteins that reduce intracellular calcium and hyperpolarize the plasma membrane causing relaxation

12. Mechanism of Action of Nitrovasodilators Nitrates become denitrated by glutathione S-transferase to release Nitric Oxide activates Guanylate Cyclase* converts GTP cGMP activates cGMP-dependent protein kinase • Activation of PKG results in phosphorylation • of several proteins that reduce intracellular calcium • causing smooth muscle relaxation

13. Increased coronary blood flow: • Large epicardial coronary arteries are dilated without impairing autoregulation in small coronary vessels • Collateral flow may be increased • Decreased preload improves subendocardial perfusion • Dilation of coronary arteries can paradoxically result in aggravation of angina - a phenomenon known as “coronary steal”

14. Pharmacokinetic Properties ofOrganic Nitrates • Hepatic first-pass metabolism is high and oral bioavailability is low for nitroglycerin (GTN) and isosorbidedinitrate (ISDN) • Sublingual or transdermal administration of these agents avoids the first-pass effect • Isosorbidemononitrate (5-ISMN) is not subject to first-pass metabolism and is 100% available after oral administration

15. Property GTN ISDN 5-ISMN Half-life (min) 3 10 280 Plasma clearance (L/min) 50 4 0.1 Apparent volume of distribution (L/kg) 3 4 0.6 Oral bioavailability (%) < 1 20 100

16. Amyl nitrate is a gas at room temperatures and can be administered by inhalation • Rapid onset, short duration (3-5 min) • GTN and ISDN have a rapid onset of action (1-3 min) when administered sublingually, but the short duration of action (20-30 min) is not suitable for maintenance therapy

17. IVnitrogylcerin can be used to treat severe recurrent unstable angina • Slowly absorbed preparations of nitrovasodilators (oral, buccal, transdermal) can be used to provide prolonged prophylaxis against angina (3-10 hrs), but can lead to tolerance (tachyphylaxis

18. Ointment. Nitroglycerin ointment (15 mg/inch) is efficacious when applied (most commonly to the chest) in strips of 0.5 to 2.0 inches. The delay in onset of action is approximately 30 minutes.

19. Because this form of the drug is effective for 4 to 6 hours, it is particularly useful for patients with severe angina or unstable angina who are confined to bed and chair. absorption is also enhanced if the paste is covered with plastic, with the edges taped to the skin.

20. Tolerance and Dependence with Nitrovasodilators • Continuous or frequent exposure to nitrovasodilators can lead to the development of complete tolerance • Transdermal GTN may provide therapeutic levels of drug for 24 hours or more, but efficacy only lasts 8-10 hrs • Nitrate-free periods of at least 12 hrs (e.g.- overnight) are recommended to avoid or reduce tachyphylaxis

21. The mechanism of tolerance is not completely understood but appears to relate to the enzymes involved in converting the nitrates to NO, or to the enzyme that produces cGMP

22. Adverse Effects of Nitrovasodilators • The major acute adverse effects of nitrovasodilators are due to excessive vasodilation • Orthostatic hypotension • Tachycardia • Severe throbbing headache • Dizziness • Flushing • Syncope

23. Sildenafil (Viagra) and for erectile dysfunction can potentiate the actions of nitrovasodilators because they inhibit the breakdown of cGMP (they should not be taken within 6 hours of taking a nitrovasodilator

24. Ca Channel Blockers

25. Chemistry of Ca++ Channel Blockers • Dihydropyridines: Nicardipine, nifedipine, nimodipine, amlodipine, and many others • Nondihydropyridines: Diltiazem, verapamil

26. Effects on Vascular Smooth Muscle • Ca++ channel blockers inhibit L-type and/or T-type voltage-dependent Ca++ channels • Little or no effect on receptor-operated channels or on release of Ca++ from SR

27. “Vascular selectivity” is seen with the Ca++ channel blockers • Decreased intracellular Ca++ in arterial smooth muscle results in relaxation (vasodilatation) -> decreased cardiac afterload (aortic pressure) • Little or no effect of Ca++-channel blockers on venous beds -> no effect on cardiac preload (ventricular filling pressure)

28. Specific dihydropyridines may exhibit greater potencies in some vascular beds (e.g.- nimodipine more selective for cerebral blood vessels, nicardipine for coronary vessels) • Little or no effect on nonvascular smooth muscle

29. Relative Cardiovascular Effects of Calcium Channel Blockers(adapted from Goodman & Gilman, 9th ed.) Verapamil ++++ ++++ +++++ +++++ Diltiazem +++ ++ +++++ ++++ Nifedipine +++++ + + 0 Nicardipine +++++ 0 + 0 Compound Coronary vasodilation Suppression of cardiac contractility Suppression of SA node Suppression of AV node

30. Desired Therapeutic Effects of Calcium Channel Blockers for Angina • Improve oxygen delivery to ischemic myocardium • Vasodilate coronary arteries • May inhibit platelet aggregation • Particularly useful in treating vasospastic angina

31. Reduce myocardial oxygen consumption Decrease afterload (no effect on preload Non-dihydropyridines also lower heart rate and decrease contractility Dihydropyridines may aggravate angina in some patients due to reflex increases in heart rate and contractility

32. Nifedipine • Nifedipine, a dihydropyridine, is a particularly effective dilator of vascular smooth muscle and is a more potent vasodilator than diltiazem or verapamil • Thus, in clinical practice, the potential negative chronotropic, inotropic, and dromotropic(on AV conduction) effects of nifedipine are seldom a problem

33. The beneficial effects of nifedipine in the treatment of angina result from its ability to reduce myocardial O2 requirements because of its afterload-reducing effect and to increase myocardial O2 delivery as a result of its dilating action on the coronary vascular bed .

34. This immediate-release formulation is no longer recommended because of concerns regarding adverse events. • An extended-release formulation using the gastrointestinal therapeutic system of drug delivery is designed to deliver 30, 60, or 90 mg of nifedipine in a single daily dose at a relatively constant rate over a 24-hour period and is useful for the treatment of chronic stable angina, Prinzmetal angina, and hypertension.

35. Adverse effects • These occur in 15% to 20% of patients and require discontinuation of medication in about 5%. Most adverse effects are related to systemic vasodilation and include headache, dizziness, palpitations, flushing, hypotension, and leg edema (unrelated to heart failure). Gastrointestinal side effects, including nausea, epigastric pressure, and vomiting, are noted in approximately 5% of patients

36. Long-acting nifedipineshould be considered as an effective and safe antianginal drug for the treatment of symptomatic patients with chronic CAD who are already receiving beta blockers, with or without nitrates. Short-acting nifedipine should ordinarily be avoided.

37. Because of its potent vasodilator effects, nifedipine is contraindicated for patients who are hypotensive or have severe aortic valve stenosis and for patients with unstable angina who are not simultaneously receiving a beta blocker in whom reflex-mediated increases in the heart rate may be harmful • Short-acting nifedipine may cause an increase in mortality.

38. Verapamil • Verapamil dilates systemic and coronary resistance vessels and large coronary conductance vessels. It slows the heart rate and reduces myocardial contractility. This combination of actions results in a reduction in myocardial O2 requirement, which is the basis for the drug's efficacy in the management of chronic stable angina.

39. Intravenous verapamil should generally not be used together with a beta blocker (given intravenously or orally), nor should a beta blocker be administered intravenously in patients receiving oral verapamil. • Both drugs can be administered orally but with caution in view of the potential for the development of bradyarrhythmias and negative inotropic effects

40. Adverse effects • Adverse effects of verapamil are noted in approximately 10% of patients and relate to systemic vasodilation (hypotension and facial flushing), gastrointestinal symptoms (constipation and nausea), and central nervous system reactions, such as headache and dizziness. A rare side effect is gingival hyperplasia, which appears after 1 to 9 months of therapy

41. Diltiazem • Diltiazem's actions are intermediate between those of nifedipine and verapamil. In clinically useful doses, its vasodilator effects are less profound than those of nifedipine, and its cardiac depressant action, on the sinoatrial and AV nodes and myocardium, is less than that of verapamil. • This profile may explain the remarkably low incidence of adverse effects of diltiazem

42. Several sustained-release formulations of diltiazem are available for once-daily treatment of systemic hypertension and angina pectoris. • The usual starting dosage of sustained-release formulations is 120 mg once daily up to a typical maintenance dosage of 180 to 360 mg once daily.

43. The maximum effect on blood pressure may not be observed until 14 days after starting therapy.

44. Second-Generation Calcium Antagonists • The second-generation calcium antagonists (e.g., nicardipine, isradipine, amlodipine, felodipine) are mainly dihydropyridine derivatives, with nifedipine being the prototypical agent.

45. Amlodipine • It causes marked coronary and peripheral dilation and may be useful in the treatment of patients with angina accompanied by hypertension. It may be used as a once-daily hypotensive or antianginal agent. Amlodipine has little, if any, negative inotropic action and may be especially useful for patients with chronic angina and LV dysfunction

46. The usual dosage of amlodipine is 5 to 10 mg once daily. • Downward adjustment of the starting dose is appropriate for patients with liver disease and older patients. • Significant changes in blood pressure are typically not evident until 24 to 48 hours after initiation. Steady-state serum levels are achieved at 7 to 8 days.

47. Beta-Adrenergic Blocking Agents • Beta blockers constitute a cornerstone of therapy for angina. In addition to their antiischemicproperties • are effective antihypertensives • antiarrhythmics • reduce mortality and reinfarction in patients after MI • reduce mortality in patients with heart failure.

48. This combination of actions makes them extremely useful in the management of stable IHD.

50. Abrupt withdrawal of beta-adrenergic blocking agents after prolonged administration can result in increased total ischemic activity in patients with chronic stable angina. Occasionally, such withdrawal can precipitate unstable angina and may, in rare cases, even provoke MI.